Inventiva S.A - Asset Resilience Ratio
Inventiva S.A (IVA) has an Asset Resilience Ratio of 13.77% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IVA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Inventiva S.A's Asset Resilience Ratio has changed over time. See what is Inventiva S.A's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Inventiva S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Inventiva S.A.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €24.58 Million | 13.77% |
| Total Liquid Assets | €24.58 Million | 13.77% |
Asset Resilience Insights
- Moderate Liquidity: Inventiva S.A has 13.77% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Inventiva S.A Industry Peers by Asset Resilience Ratio
Compare Inventiva S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Inventiva S.A (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Inventiva S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€118.97 Million ≈ $139.08 Million |
-- |
| 2023-12-31 | 0.10% | €70.00K ≈ $81.84K |
€69.56 Million ≈ $81.32 Million |
-0.80pp |
| 2022-12-31 | 0.90% | €1.05 Million ≈ $1.23 Million |
€116.00 Million ≈ $135.62 Million |
-6.33pp |
| 2021-12-31 | 7.24% | €8.83 Million ≈ $10.32 Million |
€121.98 Million ≈ $142.61 Million |
+1.96pp |
| 2020-12-31 | 5.28% | €7.34 Million ≈ $8.58 Million |
€138.92 Million ≈ $162.41 Million |
+5.28pp |
| 2017-12-31 | 0.00% | €-3.11K ≈ $-3.64K |
€74.37 Million ≈ $86.94 Million |
-- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more